Why the study?
Does amrinone cause thrombocytopenia in patients with severe congestive heart failure?
Does amrinone cause thrombocytopenia in patients with severe congestive heart failure?
Amrinone administration in severe heart failure is frequently associated with thrombocytopenia, warranting close monitoring.
Answers are grounded in this paper and cite their sources.
Amrinone may warrant platelet monitoring in severe HF; case series leaves open causality and incidence.
Amrinone, a new cardioactive drug, was administered for, on average, 27.9 d to 12 patients in severe congestive heart failure. Thrombocytopenia occurred in 4 patients, while a progressive decline in platelet numbers developed in 3 additional patients. The mechanism for these adverse effects of amrinone is unclear, but merits further study because of its frequency.
No takes yet. Share an insight, caveat, or question.
Kinney et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: